Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]

View source ↗

Summary

Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Epstein-barr Virus-positive Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• SynKIR-310

Snippet

Sponsor: Verismo Therapeutics | Conditions: B Cell Lymphoma, NHL, Adult | Phase 1 | Status: RECRUITING